Last reviewed · How we verify
NCT07444840: PBDSOO
How Does Pre-operative Biliary Drainage in Pancreatic Adenocarcinoma Affect Surgical Outcomes in Pancreatic Cancer Surgery
trial testing Pre operative biliary drainage in Pancreatic Ductal Adenocarcinoma (mPDAC) in 90 participants. Not yet recruiting.
1 April 2026
Quick facts
| Lead sponsor | East Lancashire Hospitals NHS Trust |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 1 March 2026 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 May 2026 |
Drugs / interventions tested
- Pre operative biliary drainage
Conditions studied
- Pancreatic Ductal Adenocarcinoma (mPDAC) — all drugs for Pancreatic Ductal Adenocarcinoma (mPDAC) →
- Pancreatic Ductal Adenocarcinoma (PDAC) — all drugs for Pancreatic Ductal Adenocarcinoma (PDAC) →
Sponsor
East Lancashire Hospitals NHS Trust
Who can join
18 and older, any sex, with Pancreatic Ductal Adenocarcinoma (mPDAC) or Pancreatic Ductal Adenocarcinoma (PDAC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pre-operative biliary drainage (PBD) is a procedure used to relieve bile duct obstruction, a common issue in patients with pancreatic cancer. The obstruction occurs when a tumor blocks the bile duct, leading to jaundice and other complications. While PBD can help resolve jaundice and improve liver function, its impact on the overall outcomes of pancreatic cancer surgery is still debated. Recent research has focused on whether PBD before surgery improves patient outcomes, such as surgical success, recovery time, and long-term survival. Some studies suggest that draining the bile before surgery might reduce complications like infections, liver dysfunction, and jaundice-related risks. On the other hand, other research indicates that PBD could increase the chances of infection, delays in surgery, or complications from the procedure itself, such as bile leakage or inflammation. This study will look at patients undergoing pancreaticoduodenectomy to remove their head of pancreas pancreatic ductal adenocarcinoma over 8 years, and will compare the tumour characteristics of patients who have had PBD vs those who have not. Data will be gathered from the already available histological characteristics. No treatment would be affected and no tissue would be affected. This research study will focus on oncological characteristics such as tumour progression and lymphatic spread, with overall patient survival as secondary outcome measures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07444840
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Ductal Adenocarcinoma (mPDAC)
Currently open trials in the same condition.
- NCT07144917 — Immunoparalysis After Pancreaticoduodenectomy · recruiting
Other East Lancashire Hospitals NHS Trust trials
Trials by the same sponsor.
- NCT06985979 — Exploring the Needs of HIU Patients Within the Emergency Department · completed
- NCT05964140 — The MANTRA Trial (MANdibular TRauma and Antibiotic Use) · Phase 3 · recruiting
- NCT06507124 — Rapid Examination of Acute CT · NA · completed
- NCT06100445 — Exercise Engagement in People Over 60 at Risk of Falls · recruiting
- NCT05905471 — Shoulder Fracture Interview Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07444840 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by East Lancashire Hospitals NHS Trust
- Last refreshed: 3 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07444840.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing